The effect of proton pump inhibitor uses on outcomes for cancer patients treated with immune checkpoint inhibitors: a meta-analysis.

BACKGROUND: Proton pump inhibitors (PPIs) are commonly prescribed for preventing and treating gastrointestinal ulcers. In patients with advanced cancer, it is unclear whether concomitant use of immune checkpoint inhibitors (ICIs) and PPIs could result in poorer outcomes. This study investigates the impact of PPIs on the survival of cancer patients treated with ICIs.
METHODS: PubMed, MEDLINE, EMBASE, and the Cochrane Library databases were searched from January 1, 1970 to June 2, 2020 for studies reporting the prognoses of cancer patients receiving antitumor therapies including ICIs with or without PPIs. The primary and secondary endpoints were overall survival (OS) and progression-free survival (PFS), respectively. Hazard ratios (HRs) with a 95% confidence interval (CI) were reported to express the effectiveness of ICIs in PPI users compared to non-PPI users, using a random effects model.
RESULTS: Five studies were identified comprising 1,167 cancer patients. Concomitant use of PPIs with ICIs did not result in statistically significant changes in OS (HR 0.996; 95% CI: 0.486-1.447) and PFS (HR 0.858; 95% CI: 0.388-1.328). Statistical testing suggested heterogeneity among studies. Sensitivity analyses confirmed the stability of our results.
CONCLUSIONS: Concomitant ICI-PPI therapy does not appear to be significantly associated with OS or PFS, and further research on the effect of individual ICIs in different cancer patients is needed. 2020 Annals of Translational Medicine. All rights reserved.

Introduction

In the past decade, immune checkpoint inhibitors (ICIs) including cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) inhibitors, programmed cell death-1 (PD-1) inhibitors, and programmed cell death-ligand 1 (PD-L1) inhibitors, have shown breakthrough efficacy in the management of a number of advanced malignancies (1).

Evidence has shown that the gut microbiome is related to the response to ICI immunotherapy (2-5). For example, concomitant use of broad-spectrum antibiotics is increasingly considered to play an important role in ICI therapeutic outcomes, as the diversity and abundance of the gut microbiome are associated with broad spectrum antibiotics (6,7).

Proton pump inhibitors (PPIs), acting through the irreversible inhibition of the hydrogen/potassium pump (H+/K+-ATPase pump) in the gastric parietal cells, could change the pH value of the gut, thus causing changes to the gut microbiome.

Recent studies have shown a variable influence of PPIs on the efficacy of ICIs, ranging from no difference to a negative impact (8-14). Currently, the role of concomitant PPI use on ICIs’ therapeutic efficacy remains controversial, thus a meta-analysis may provide a better understanding of this issue. To our knowledge, this is the first meta-analysis to systematically evaluate the association between PPI use and the clinical efficacy of ICIs. Assessing the impact on the clinical efficacy of adding PPI use to ICI immunotherapy would help to establish therapeutic decision-making algorithm among cancer patients who were also potential candidates for PPIs. We present the following article in accordance with the PRISMA reporting checklist (available at http://dx.doi.org/10.21037/atm-20-7498).

Methods

Registration

This study was registered in PROSPERO with registration number CRD42020190094.

Retrieval of studies

This meta-analysis was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement (15).

The search was performed from January 1, 1970 to June 2, 2020 and included studies written in English in PubMed, MEDLINE, EMBASE, and the Cochrane Library databases using the terms (PPI or proton pump inhibitor) AND (PD-1 or PD-L1 or CTLA-4 or “immune checkpoint inhibitors”) AND survival (Appendix 1).

Studies that satisfied all of the following criteria were included: (I) patients: patients were diagnosed with cancer, and had received antitumor therapy including ICIs alone (CTLA-4 inhibitors and PD-1/L1 inhibitors) or in combination; (II) intervention: PPIs were prescribed before, during, or after the antitumor therapeutic course; (III) comparison: the experimental group received PPIs but the control group did not; (IV) outcome: complete outcomes that measured overall survival (OS) and progression-free survival (PFS) were extracted.

Initially, citations containing the key terms of the search were evaluated by their titles and abstracts. Subsequently, full texts of relevant citations were further assessed for possible inclusion in the systematic review. Conflicts amongst the researchers regarding study selection were resolved by discussion, referring back to the original article until consensus was achieved between all authors.

Quality evaluation

The Newcastle-Ottawa quality assessment scale (NOS) was adopted to evaluate the quality of each study on these items: patient selection, comparability of groups, and assessment of outcome (16). Studies with less than six stars were regarded as relatively low quality and were excluded. Two investigators independently evaluated the risk of bias, and disagreements were resolved through discussion until consensus was achieved.

Data extraction

Two independent investigators separately screened the titles and abstracts of eligible studies by applying the inclusion criteria, and any discrepancies between them were resolved by consensus between all authors. Information was extracted from the eligible articles as follows (where available): authors, year of publication, country, title, number of patients, type of cancer, type of ICIs and PPIs, PFS, OS, and hazard ratios (HRs). Missing data was handled by contacting the authors of the studies for unreported data or additional details.

Data analysis

The primary and secondary outcomes were OS and PFS, respectively. HRs with a 95% confidence interval (CI) were calculated to express the effectiveness of ICIs in PPI users compared to non-PPI users. Heterogeneity among the studies was evaluated by I2 statistics. When I2>50% and/or P<0.10, the heterogeneity was considered statistically significant. Under this circumstance, a random effects model was adopted to pool the HRs; otherwise, a fixed effects model was adopted (17).

Publication bias assessment was not performed due to the limited number of studies (below 10) included in each analysis. Sensitivity analyses were performed by individual exclusion of each study for each outcome to assess their effect on the pooled outcome hazard ratio. All statistical analyses were conducted on Stata software (Version 15.0, Stata Corporation, College Station, TX, USA).

Results

Search results

A total of 1,167 patients from five studies were eligible for quantitative analysis (18-22) ().

Figure 1

Flowchart of study selection procedure.

The basic characteristics of the enrolled studies are shown in . All of the studies were retrospective. Among them, four studies were complete cohort studies and one study provided only an abstract. The included studies were published between 2016 and 2020 (with four of the studies published in 2019 and 2020) from China, the United States, Spain, and Switzerland/Netherlands/USA.

Table 1

The characteristics of enrolled studies

Author	Year	Country	Type of cancer	Sample (Y/N)	Type of PPIs	Type of ICIs	PPI use window	Evaluation criteria	Follow up time	Quality evaluation	Outcome
Afzal MZ et al.	2019	USA	Melanoma	120 (29/91)	Omeprazole (58.6%)	Ipilimumab, pembrolizumab, nivolumab alone or in combination	Taking PPI at the time of ICI initiation	NR	NR	7 stars	OS, PFS, odds of IrAE above grade 3
Chalabi M et al.	2020	Worldwide	NSCLC	757 (235/522)	Domeprazole, pantoprazole, lansoprazole, rabeprazole, esomeprazole, dexlansoprazole	Atezolizumab	Within 30 days before or after the start of ICI	RECIST 1.1	19.2 months	8 stars	OS, PFS
Failing JJ et al.	2016	USA	Melanoma	80 (17/63)	Omeprazole, pantoprazole, esomeprazole, lansoprazole	Ipilimumab	At the start of ipilimumab treatment	RECIST 1.1	49 months	8 stars	OS, PFS,odds of IrAE above grade 3
Iglesias-Santamaría A et al.	2020	Spain	All kinds of malignancy	101 (78/23)	NR	Ipilimumab+ nivolumab, nivolumab, pembrolizumab, atezolizumab	NR	2017 iRECIST	26 months	8 stars	OS, PFS
Zhao S et al.	2019	China	NSCLC	109 (40/69)	NR	Pembrolizumab, nivolumab, SHR-1210	Within 1 month before or after the first dose of ICIs	RECIST 1.1	28 months	8 stars	OS, PFS

NR, not reported; NSCLC, non-small cell lung cancer; OS, overall survival; PFS, progression-free survival; Y/N, proton pump inhibitor (PPI) use/no PPI use.

PPIs were given to 52.0% of patients. In regard to the time of PPI use, two studies reported patients taking PPIs at the time of ICI initiation, two studies reported patients taking PPIs within 1 month before or after the first dose of ICIs, and one study did not report the time window of PPI use. In regard to ICI type, two studies included anti-CTLA-4 inhibitors and/or anti-PD-1/L1 inhibitors, one study included anti-CTLA-4 inhibitors alone, one study used anti-PD-1 inhibitors alone, and a further study included anti-PD-L1 inhibitors alone.

Main results

OS was not significantly associated with the concomitant use of PPIs (HR =0.966, 95% CI: 0.486–1.447; ). Owing to high heterogeneity (I2=74.3%), a random effects model was used. The subgroup analyses were performed based on the type of cancer and the type of ICI drug. (NSCLC: HR =1.103, 95% CI: 0.353–1.854, P=0.014, I2=83.4%; non-NSCLC: HR =0.788, 95% CI: 0.277–1.298, P=0.212, I2=35.5%). The subgroup analyses based on the type of ICI drug obtained the same results.

Figure 2

The associations between PPI use and overall survival (A) and progression-free survival (B) in cancer patients treated with ICI. PPI, proton pump inhibitor; ICI, immune checkpoint inhibitor.

PFS was not significantly associated with the concomitant use of PPIs (HR =0.858, 95% CI: 0.388–1.328; ). Owing to high heterogeneity (I2=87.7%), a random effects model was used. The subgroup analyses were performed based on the type of cancer and the type of ICI drug. (NSCLC: HR =1.173, 95% CI: 0.815–1.521, P=0.160, I2=49.3%; non-NSCLC: HR =0.680, 95% CI: 0.173–1.042, P=0.050, I2=66.6%). The sensitivity analyses revealed that the results were not dominated by any single study (). Subgroup analyses based on the type of ICI drug obtained the same results.

Figure 3

Sensitivity analysis of overall survival and (A) progression-free survival (B).

Subgroup analyses of the effect of types of PPI or the timing and course of PPIs were not possible due to incomplete data.

Publication bias assessment was not performed due to the limited number of studies (below 10) included in each analysis.

Discussion

Previous evidence has shown that an intact gut microbiota is necessary in order to create the immune response and provide ICI treatment benefits to cancer patients (23,24). Unlike previous studies, this study focused on the effect of the interaction between PPIs and ICIs. Our conclusion is that use of PPIs does not appear to affect the clinical efficacy of ICIs. This result is contrary to previous theories suggesting that antibiotic use which alters the microbiota is associated with a poorer response to immunotherapy.

PPI-driven gastric hypochlorhydria can cause significant changes in the gut microbiota composition, and PPI use was therefore reported to be associated with decreased bacterial richness, gut dysbiosis, and the promotion of T-cell tolerance. Hypochlorhydria also promotes a reduction in microbial diversity and the growth of microbes that have genotoxic potential, with an increase in the nitrate/nitrite reductase bacterial functions involved in cancer development (25-27). The effect of PPIs is not only limited to influencing gut microbiota but can also affect tumor growth. It has been reported that PPIs play a role in regulating the acidic microenvironment of tumor cells and in facilitating the proliferation, progression, and metastasis of tumors (28,29). PPIs also sensitize the resistant tumors to chemotherapeutic and immunotherapeutic effects (30,31). Thus, it is hard to predict the net result of the changes caused by PPIs for cancer patients who are on ICI immunotherapy.

Assessing the impact on the clinical efficacy of adding PPI use to ICI immunotherapy would help to establish a therapeutic decision-making algorithm for physicians treating cancer patients who are also potential candidates for PPIs.

The limitations of this meta-analysis were as follows: Firstly, it consisted of retrospective studies with heterogeneous populations with a diversity of cancer types, stages, and patient characteristics. Secondly, the type of PPI, indication, time frame and duration of PPIs were not available by search. Finally, antitumor agents other than ICIs as well as other concomitant drugs other than PPIs used for patients were not taken into consideration.

Therefore, further prospective studies, especially of patients with esophageal cancer or gastrointestinal cancer, are necessary to identify which specific phenotypes of gut microbiota may strengthen or weaken antitumor immune responses as a result of the use of PPIs. Validation of the evaluation results of co-administration of PPIs and ICIs from completed or ongoing randomized controlled trials is needed, taking into account that prospective trials of PPIs on outcome after ICI may be impracticable.

Conclusions

In summary, the current meta-analysis evaluating the aforementioned studies did not suggest that the concomitant use of PPIs and ICIs in cancer patients was associated with a significant difference in OS or PFS. Clinical trials to investigate the modulating mechanism of the gut microbiome in order to enhance ICI efficacy should be actively conducted.

The article’s supplementary files as